Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon

期刊论文
发表日期：

2024年11月27日

查看全文

Andrea Pretta,
Pina Ziranu,
Eleonora Perissinotto,
Filippo Ghelardi,
Federica Marmorino,
Riccardo Giampieri,
Mariangela Puci,
Maria Caterina De Grandis,
Eleonora Lai,
Vincenzo Nasca,
Paolo Ciraci,
Marco Puzzoni,
Krisida Cerma,
Carolina Sciortino,
Ada Taravella,
Gianluca Pretta,
Lorenzo Giuliani,
Camilla Damonte,
Valeria Pusceddu,
Giovanni Sotgiu,
Rossana Berardi,
Sara Lonardi,
Francesca Bergamo,
Filippo Pietrantonio,
Chiara Cremolini,
Mario Scartozzi

摘要

Background

Despite a reduction of both incidence and mortality from CRC, recent studies have shown an increase in the incidence of early-onset CRC (EO-CRC). Data on this setting are limited. The aim of our study was to evaluate the clinical and molecular profiles of metastatic EO-CRC patients in order to identify differences compared to a late-onset CRC (LO-CRC) control group.

Methods

We retrospectively collected data from 1272 metastatic colorectal cancers from 5 different Italian Institutions. The main objective was to the evaluate clinical outcome for EO-CRC patients in comparison to patients included in the control group.

Results

In the overall population, mOS was 34,7 in EO-CRC pts vs 43,0 months (mo) (p < 0,0001). In the RAS/BRAF mutated subgroup mOS in EO-CRC pts was 30,3 vs 34,0 mo (p = 0,0156). In RAS/BRAF wild-type EO-CRC mOS was 43,0 vs 50,0 mo (p = 0,0290). mPFS was 11,0 in EO-CRC pts vs 14,0 mo (p < 0,0001).

Conclusion

Findings indicate a general worse prognosis for patients with early-onset colorectal cancer compared to late-onset patients. Interestingly this seems to occur regardless of the molecular status. These observations might have a considerable impact on clinical practice and research.